Independent Advisor Alliance Purchases 3,816 Shares of Biogen Inc. $BIIB

Independent Advisor Alliance raised its position in shares of Biogen Inc. (NASDAQ:BIIB) by 175.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,987 shares of the biotechnology company’s stock after acquiring an additional 3,816 shares during the quarter. Independent Advisor Alliance’s holdings in Biogen were worth $1,054,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of BIIB. WPG Advisers LLC boosted its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares during the last quarter. Accredited Wealth Management LLC boosted its position in Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares during the last quarter. First Horizon Corp bought a new stake in Biogen during the fourth quarter valued at $30,000. WFA of San Diego LLC bought a new stake in Biogen during the second quarter valued at $32,000. Finally, GoalVest Advisory LLC bought a new stake in Biogen during the fourth quarter valued at $35,000. Institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $192.95 on Friday. The firm’s 50-day moving average price is $185.21 and its 200-day moving average price is $179.33. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97. The firm has a market capitalization of $28.49 billion, a P/E ratio of 20.70, a P/E/G ratio of 1.68 and a beta of 0.19. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the business earned $3.02 earnings per share. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts anticipate that Biogen Inc. will post 14.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on BIIB shares. Wedbush upped their price target on shares of Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research report on Thursday, April 30th. HSBC upped their price target on shares of Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a research report on Tuesday, March 17th. Wolfe Research set a $231.00 price target on shares of Biogen in a research report on Monday, February 9th. Stifel Nicolaus upped their price objective on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a report on Friday, February 6th. Finally, Wells Fargo & Company upped their price objective on shares of Biogen from $190.00 to $200.00 and gave the company an “equal weight” rating in a report on Sunday, February 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $215.62.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said its Phase 2 CELIA study of diranersen (BIIB080), a tau-targeting Alzheimer’s drug, showed robust reductions in tau pathology and signals of slowed cognitive decline, prompting the company to advance the program into late-stage development. Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
• Positive Sentiment: Goldman Sachs reiterated a Buy rating and lifted its price target to $250, while Oppenheimer raised its target to $300 and Evercore initiated coverage with an Outperform rating, reinforcing optimism around Biogen’s valuation and pipeline. Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250 Oppenheimer raises Biogen price target to $300 from $275, maintains Outperform rating
• Positive Sentiment: Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, adding commercial products SYFOVRE and EMPAVELI and potentially improving near-term growth prospects. Biogen Completes Acquisition of Apellis Pharmaceuticals
• Neutral Sentiment: Some analysts remain cautious, saying mixed Alzheimer’s data and pipeline uncertainty still create a balanced risk/reward profile despite the recent rally. Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained
• Negative Sentiment: The CELIA study missed its primary endpoint, and a law firm has already announced an investigation into possible securities-law issues tied to the stock’s move after the data release, which could add headline risk. Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny – Contact Levi & Korsinsky for Details

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.